ProKidney Corp. (NASDAQ:PROK - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $1.51, but opened at $1.55. ProKidney shares last traded at $1.72, with a volume of 375,998 shares trading hands.
Analyst Upgrades and Downgrades
PROK has been the topic of a number of recent research reports. Bank of America cut their price objective on shares of ProKidney from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Wednesday, September 4th. Guggenheim began coverage on ProKidney in a research note on Tuesday, September 10th. They issued a "buy" rating and a $6.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on ProKidney in a research report on Monday, September 30th. They set a "neutral" rating for the company. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $4.50.
View Our Latest Stock Report on PROK
ProKidney Stock Up 11.9 %
The stock has a market cap of $492.91 million, a PE ratio of -3.07 and a beta of 1.27. The stock's fifty day moving average price is $1.83 and its 200 day moving average price is $2.13.
ProKidney (NASDAQ:PROK - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). On average, equities research analysts expect that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.
Hedge Funds Weigh In On ProKidney
Hedge funds have recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in ProKidney during the 3rd quarter valued at $41,000. Intech Investment Management LLC bought a new stake in shares of ProKidney in the third quarter worth $46,000. AQR Capital Management LLC bought a new position in ProKidney in the second quarter valued at about $50,000. The Manufacturers Life Insurance Company purchased a new position in ProKidney in the second quarter worth about $60,000. Finally, Castleview Partners LLC purchased a new position in ProKidney in the third quarter worth about $63,000. Hedge funds and other institutional investors own 51.59% of the company's stock.
About ProKidney
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Read More
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
